These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33754810)

  • 1. Metformin in the era of new antidiabetics.
    Rajjoub Al-Mahdi EA; Barrios V; Zamorano JL
    Future Cardiol; 2021 May; 17(3):475-485. PubMed ID: 33754810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
    Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
    Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 4. The position of SGLT2 inhibitors in current medicine.
    Prázný M
    Vnitr Lek; 2020; 66(2):82-88. PubMed ID: 32942881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular Effects of Antidiabetic Therapies].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin: Past, Present, and Future.
    Chaudhary S; Kulkarni A
    Curr Diab Rep; 2024 Jun; 24(6):119-130. PubMed ID: 38568468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia.
    Bora VR; Gohel D; Singh R; Patel BM
    Mol Cell Biochem; 2023 Apr; 478(4):807-820. PubMed ID: 36098898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
    Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral hypoglycemic agents and metformin in the treatment of type II non-insulin-dependent diabetes].
    Isnard F
    Sem Hop; 1983 Dec; 59(49):3437-8. PubMed ID: 6320423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modern antihyperglycaemic agents--what is the patient benefit?].
    Siegmund T
    MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxicity of Metformin and Hypoglycemic Therapies.
    Akhter MS; Uppal P
    Adv Chronic Kidney Dis; 2020 Jan; 27(1):18-30. PubMed ID: 32146997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The right place for metformin today.
    Schernthaner G; Schernthaner GH
    Diabetes Res Clin Pract; 2020 Jan; 159():107946. PubMed ID: 31778746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators.
    Kameda T; Kumamaru H; Nishimura S; Kohsaka S; Miyata H
    Curr Med Res Opin; 2020 May; 36(5):749-756. PubMed ID: 32050809
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral antidiabetic drugs in treatment of type 1 diabetes mellitus].
    Brunerová L; Brož J
    Vnitr Lek; 2016; 62(12):998-1003. PubMed ID: 28139129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.